Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2016

01-02-2016 | Epidemiology

Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens

Authors: D. G. Evans, F. Lalloo, S. Howell, S. Verhoef, E. R. Woodward, A. Howell

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Login to get access

Abstract

The aim of this study is to delineate more clearly the prevalence of HER2+ breast cancer in women with germline BRCA1/2 mutations. For this purpose, we analysed primary mutation screens on women with breast cancer with unequivocal HER2 amplification and assessed the proportion of BRCA1 and BRCA2 breast cancers that were HER2+ comparing this with the existing literature. The results are that 1063 primary BRCA screens had confirmed tumour HER2 status. If HER2+ only 2.5 % (4/156) and 3.2 % (5/156) of women had a BRCA1 or BRCA2 mutation identified respectively; compared to 27.7 % (115/415) and 8.2 % (34/415) with triple negative tumours. Only 2.1 % (4/195) women with BRCA1-related breast cancer had HER2 amplified breast cancers rising to 6.8 % (n = 12, p = 0.04) in BRCA2. These rates are in keeping with most of the existing literature except a recent large multicenter report which documented higher rates but with no control group. The study concluded that true HER2-amplified breast cancers are rare amongst BRCA1 mutation carriers and are less common in BRCA2 than background rates.
Literature
1.
Lakhani SR, Van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318CrossRefPubMed
2.
Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180CrossRefPubMed
3.
Spurdle AB, Couch FJ, Parsons MT et al (2014) Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 16(6):3419PubMedCentralCrossRefPubMed
4.
5.
Parmigiani G, Berry DA, Aquilar O (1998) Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–148PubMedCentralCrossRefPubMed
6.
Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98(12):2015PubMedCentralCrossRef
7.
Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130CrossRefPubMed
8.
Evans DG, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480PubMedCentralCrossRefPubMed
9.
Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490CrossRefPubMed
10.
Evans DG, Lalloo F, Cramer A et al (2009) Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 46(12):811–817CrossRefPubMed
11.
Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC (2010) Incorporating tumor pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 12(3):R28PubMedCentralCrossRefPubMed
12.
Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF (2014) Antoniou AC; consortium of investigators of modifiers of BRCA1/2; breast cancer association consortium. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumor pathology and web interface. Br J Cancer 110(2):535–545PubMedCentralCrossRefPubMed
13.
Fischer C, Kuchenbäcker K, Engel C et al (2013) Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 50(6):360–367CrossRefPubMed
14.
Mavaddat N, Barrowdale D, Andrulis IL et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev 21(1):134–147CrossRef
15.
Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O’Doherty A, Quinn CM, Green AJ, Bracken A, Geraghty JG (2015) Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer. Eur J Surg Oncol 41(5):641–646CrossRefPubMed
16.
Lagos-Jaramillo VI, Press MF, Ricker CN, Dubeau L, Mai PL, Weitzel JN (2011) Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat 130(1):281–289PubMedCentralCrossRefPubMed
17.
Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ (2010) Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 12(1):R12PubMedCentralCrossRefPubMed
18.
Eerola H, Heinonen M, Heikkilä P, Kilpivaara O, Tamminen A, Aittomäki K, Blomqvist C, Ristimäki A, Nevanlinna H (2008) Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 10(1):R17PubMedCentralCrossRefPubMed
19.
Chéreau E, Uzan C, Balleyguier C, Chevalier J, de Paillerets BB, Caron O, Rimareix F, Mathieu MC, Koskas M, Bourgier C, André F, Dromain C, Delaloge S (2010) Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. Clin Breast Cancer 10(2):113–118CrossRefPubMed
20.
Curtit E, Benhamo V, Gruel N, Popova T, Manie E, Cottu P, Mariani O, Stoppa-Lyonnet D, Pivot X, Stern MH, Vincent-Salomon A (2015) First description of a sporadic breast cancer in a woman with BRCA1 germline mutation. Oncotarget. 6(34):35616–35624PubMed
21.
Smith MJ, Gifford FL, Lalloo F, Newman WG, Evans DG (2012) High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered? Breast Cancer Res Treat 134(2):895–897CrossRefPubMed
22.
Evans DG, Ingham SL, Buchan I et al (2013) Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers. Cancer Epidemiol Biomark Prev 22(12):2269–2276CrossRef
23.
Wilson JR, Bateman AC, Hanson H et al (2010) A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 47(11):771–774CrossRefPubMed
24.
Bougeard G, Renaux-Petel M, Flaman JM et al (2015) Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33(21):2345–2352CrossRefPubMed
25.
Copson E, Eccles B, Maishman T et al (2013) Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. J Natl Cancer Inst 105(13):978–988CrossRefPubMed
Metadata
Title
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens
Authors
D. G. Evans
F. Lalloo
S. Howell
S. Verhoef
E. R. Woodward
A. Howell
Publication date
01-02-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3697-z

Other articles of this Issue 3/2016

Breast Cancer Research and Treatment 3/2016 Go to the issue

Epidemiology

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers

Epidemiology

Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community

Brief Report

Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm

Preclinical study

High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation

Erratum

Erratum to: CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis

Clinical trial

The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits